Trial Profile
A prospective, multicentre, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Masitinib (Primary) ; Gemcitabine
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OVARIAN; OVARIO
- Sponsors AB Science
- 07 Dec 2020 Status changed from active, no longer recruiting to completed.
- 03 Apr 2020 Planned End Date changed from 1 Dec 2020 to 1 Jun 2020.
- 03 Apr 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2020.